Pharmaceuticals, Menarini: further boost for the company from Cornut
Aleotti: "Decision follows our philosophy"
Florence, March 22. – The Menarini pharmaceutical group, led by the Aleotti family, has decided to entrust the presidency of the company to an external manager from a large multinational, Dr. Eric Cornut. The new presidency will be effective from June. It is Lucia Aleotti herself, current president of the pharmaceutical group, together with her brother 
Alberto Giovanni, vice president, to give the announcement to the employees and the press.
“Entrusting the presidency of the company to an external manager with great experience is a weighted decision shared with our entire Board of Directors, in line with our philosophy of quickly grasping the signals coming from the competitive context in which we operate” declared Lucia Aleotti. “Menarini is growing in many geographical areas and in new research areas, both pharmaceutical and technological. Eric Cornut already has a lot of transversal experience in these areas and will be able to give the company a further boost”.
No disengagement for the Aleotti family: “On the contrary. We will be able to devote more time and energy to the search for possible strategic acquisitions, combining the dynamism and values of a family business with the experience of the future president” confirmed Alberto Giovanni Aleotti.
Eric Cornut said: “I was able to get to know Menarini first as an external observer, then as a member of the Board of Directors, increasingly appreciating its values and philosophy that make it a rather unique company in the international context, with enviable development potential. I am honored to be able to contribute to this path of evolution and growth of the company".
Eric Cornut, 60, studied at the University of Basel and at the University of California at Barkeley in the USA. He worked as chief ethics, compliance and policy officer at Novartis and has more than 20 years of experience. He spent twenty years with the Swiss company and also worked as interim general manager in the European Federfarma (Efpia) from December 2016 to April 2017. Also in Novartis he was president of the Japanese office from 2012 to 2016. He holds the role of member of the Supervisory Board to EG Arzneimittel Aktiengesellschaft since 2016. He joined the Menarini Board of Directors in June 2017 as an independent. Three out of five members are now outside the corporate ownership
Related news: Menarini announces the new governance
